Proteon Therapeutics Inc.
Proteon Therapeutics Inc. is listed today as Protara Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2017 | $22 M | Private placement after listing | $10 to $50 million | equity, options | SEC | |
| May 2014 | $30 M | No. 3 | $10 to $50 million | equity | SEC | |
| Sep 2013 | $4 M | No. 2 | $2 to $10 million | equity, debt, options | SEC | |
| Aug 2011 | $15 M | No. 1 | $10 to $50 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Proteon Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2017).
SEC Form D · Aug 2017
The industry group it chose in its notices: Biotechnology.
SEC Form D · Aug 2017
That is all the official record says: Proteon Therapeutics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Proteon Therapeutics Inc. are on record.
Investors#
19 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Abingworth LLP | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Deerfield International Master Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, director (Form 3, 2017) | SEC Form 3 |
| Deerfield Management Company, L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, director (Form 3, 2017) | SEC Form 3 |
| Deerfield Mgmt III, L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, director (Form 3, 2017) | SEC Form 3 |
| Deerfield Mgmt IV, L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, director (Form 3, 2017) | SEC Form 3 |
| Deerfield Mgmt L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, director (Form 3, 2017) | SEC Form 3 |
| Deerfield Partners, L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, director (Form 3, 2017) | SEC Form 3 |
| Deerfield Private Design Fund III, L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, director (Form 3, 2017) | SEC Form 3 |
| Deerfield Private Design Fund IV, L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, director (Form 3, 2017) | SEC Form 3 |
| Deerfield Special Situations Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, director (Form 3, 2017) | SEC Form 3 |
| Deerfield Special Situations International Master Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Pharmstandard International S.A. | Company | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Prism Venture Partners V-A LP | Venture capital | not stated | not stated | Held Series A, A-1, B, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Prism Venture Partners V L.P. | Venture capital | not stated | not stated | Held Series A, A-1, B, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Public Joint Stock Co Pharmstandard | Other | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Skyline Venture Management IV, LLC | Venture capital | not stated | not stated | Held Series A, A-1, B, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Skyline Venture Partners Qualified Purchaser Fund IV L.P. | Venture capital | not stated | not stated | Held Series A, A-1, B, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| TVM Life Science Ventures VI GmbH & Co KG | Venture capital | not stated | not stated | Held Series A, A-1, B, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| TVM Life Science Ventures VI LP | Venture capital | not stated | not stated | Held Series A, A-1, B, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 22 investors.
Largest shareholders today
Institutions holding Protara Therapeutics, Inc. shares, as of Sep 30, 2026.
- BlackRock, Inc.$11 M6.02%
- Millennium Management LLC$9 M5.03%
- Velan Capital Investment Management LP$9 M4.62%
- Rosalind Advisors, Inc.$7 M3.90%
- Blackstone Inc.$7 M3.84%
- Vanguard Capital Management LLC$7 M3.74%
- Citadel Advisors LLC$6 M3.39%
- Sio Capital Management, LLC$6 M3.23%
- Baker Bros. Advisors LP$6 M2.99%
- Acorn Capital Advisors, LLC$5 M2.85%
- Marshall Wace, LLP$5 M2.51%
- 5AM Venture Management, LLC$4 M2.22%
- Geode Capital Management, LLC$4 M2.17%
- Integral Health Asset Management, LLC$4 M2.03%
- Qube Research & Technologies Ltd$4 M1.90%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Daniel P. Gottlieb | Mr. Gottlieb is the Vice President of Corporate Development of the Issuer. | Aug 2017 |
| E. Scott Toner | Mr. Toner is the Senior Vice President of Marketing of the Issuer. | Aug 2017 |
| George A. Eldridge | Mr. Eldridge is the Chief Financial Officer, Senior Vice President, Treasurer and Assistant Secretary of the Issuer. | Aug 2017 |
| Matthew P. Kowalsky | Mr. Kowalsky is the Vice President of Legal and the Secretary of the Issuer. | Aug 2017 |
| Steven K. Burke, M.D. | Dr. Burke is a Senior Vice President and the Chief Medical Officer of the Issuer. | Aug 2017 |
| Timothy P. Noyes | Mr. Noyes is the President and Chief Executive Officer of the Issuer. | Aug 2017 |
| George P. Eldridge | Executive officer | May 2014 |
| Steven K. Burke | Executive officer | May 2014 |
| Timothy Noyes | Executive officer | May 2014 |
| Dean D. Profis | Executive officer | Feb 2014 |
| Dean G. Profis | Executive officer | Aug 2011 |
| Garen J. Bohlin | Director | Aug 2017 |
| Hubert J. Birner, Ph. D. | Director | Aug 2017 |
| John G. Freund, M.D. | Director | Aug 2017 |
| Jonathan G. Leff | Director | Aug 2017 |
| Paul J. Hastings | Director | Aug 2017 |
| Scott A. Canute | Director | Aug 2017 |
| Tim G. Haines | Director | Aug 2017 |
| Timothy P. Noyes | Mr. Noyes is the President and Chief Executive Officer of the Issuer. | Aug 2017 |
| Tony G. Kingsley | Director | Aug 2017 |
| Brendan Nicholas O'Leary | Director | May 2014 |
| Dmitry D. Kobyzev | Director | May 2014 |
| F. Nicholas Franano | Director | May 2014 |
| Gregory D. Phelps | Director | May 2014 |
| Hubert D. Birner | Director | May 2014 |
| John G. Freund | Director | May 2014 |
| Tim D. Haines | Director | May 2014 |
| Timothy Noyes | Director | May 2014 |
| Todd D. Foley | Director | May 2014 |
| Stephen D. Hoffman | Director | Feb 2014 |
| David G. Lowe | Director | Aug 2011 |
| Hubert G. Birner | Director | Aug 2011 |
| Steven G. St. Peter | Director | Aug 2011 |
About
American pharmaceutical company.
Went public since 2014. Its SEC number is that of a company listed on a stock exchange.